Care Capital: VC Post-2001
This article was originally published in Start Up
Executive SummaryCare Capital's focus on later-stage programs--driven by its ex-Big Pharma partners' own expertise in more advanced development and marketing--happily coincided with the lower-risk, closer-to-market models which have become fashionable with private and public investors since the 2001 downturn. Does this VC firm have the right model at the right time?
You may also be interested in...
It has been a bumpy ride for some of the (still modest) number of European biotechs listed on Nasdaq, for various reasons. Yet most expect the direct-to-Nasdaq trend to continue. Europe’s public markets simply cannot compete.